Daily GLP-1 Pill Shows Promise for Weight Loss
- * Title: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in peopel with type 2 diabetes (ATTAIN-2) * Journal: The Lancet *...
- * Provided by: University of Texas Health Science Center at Houston * Website: http://www.uthouston.edu/
- * topic: Daily oral GLP-1 pill a promising alternative to injectables for weight loss.
Here’s a breakdown of teh information provided in the text:
Research Article:
* Title: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in peopel with type 2 diabetes (ATTAIN-2)
* Journal: The Lancet
* Authors: Deborah B Horn et al.
* Study Type: Phase 3, double-blind, randomised, multicentre, placebo-controlled trial
* DOI: 10.1016/s0140-6736(25)02165-8
* publication Year: 2025
Source of Information:
* Provided by: University of Texas Health Science Center at Houston
* Website: http://www.uthouston.edu/
News Article/Release Information:
* topic: Daily oral GLP-1 pill a promising alternative to injectables for weight loss.
* Date: November 23, 2025
* Citation: Daily oral GLP-1 pill a promising alternative to injectables for weight loss, clinical trial finds (2025, November 23)
In essence, this text describes a new research study published in The Lancet about an oral medication (orforglipron) for obesity adn type 2 diabetes, and it notes that the information is being shared by the University of Texas Health Science Center at Houston.